Low-grade prostate cancer diverges early from high grade and metastatic disease

Cancer Science

Volumn 105, Issue 8, 2014, Pages 1079-1085

  Vanderweele, David J ^a,b   Brown, Christopher D ^a,b,c   Taxy, Jerome B ^b,d   Gillard, Marc ^b   Hatcher, David M ^b   Tom, Westin R ^b   Stadler, Walter M ^b   White, Kevin P ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

Carcinoma genetics; Exomes; Genetic heterogeneity; Multiple primary neoplasms; Prostatic neoplasms

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; EXOME; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LASER MICRODISSECTION; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; SOMATIC MUTATION;

CARCINOMA/GENETICS; EXOMES; GENETIC HETEROGENEITY; MULTIPLE PRIMARY NEOPLASMS; PROSTATIC NEOPLASMS;

AGED; DNA MUTATIONAL ANALYSIS; HUMANS; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS;

EID: 84904701929     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12460     Document Type: Article

References (32)

1. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9: 138-41.
2. Eggener SE, Scardino PT, Walsh PC et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185: 869-75.
3. Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI. Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes? Am J Surg Pathol 2012; 36: 1346-52.
4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
5. Andriole GL, Crawford ED, Grubb RL 3rd et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-9.
6. Schröder FH, Hugosson J, Roobol MJ et al. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981-90.
7. Mohler J, Bahnson RR, Boston B et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010; 8: 162-200.
8. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157: 120-34.
9. Berger MF, Lawrence MS, Demichelis F et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470: 214-20.
10. Barbieri CE, Baca SC, Lawrence MS et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012; 44: 685-9.
11. Grasso CS, Wu Y-M, Robinson DR et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239-43.
12. Kumar A, White TA, MacKenzie AP et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci USA 2011; 108: 17087-92.
13. Taylor BS, Schultz N, Hieronymus H et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
14. Robbins CM, Tembe WA, Baker A et al. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome Res 2011; 21: 47-55.
15. Boyd LK, Mao X, Xue L et al. High-resolution genome-wide copy-number analysis suggests a monoclonal origin of multifocal prostate cancer. Genes Chromosom Cancer 2012; 51: 579-89.
16. Sowalsky AG, Ye H, Bubley GJ, Balk SP. Clonal progression of prostate cancers from Gleason grade 3 to grade 4. Cancer Res 2013; 73: 1050-5.
17. Kovtun IV, Cheville JC, Murphy SJ et al. Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer. Cancer Res 2013; 73: 3275-84.
18. Meyer M, Kircher M. Illumina sequencing library preparation for highly multiplexed target capture and sequencing. Cold Spring Harb Protoc 2010; 2010: pdb.prot5448.
19. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-60.
20. Li H, Handsaker B, Wysoker A et al. The sequence alignment/map format and SAMtools. Bioinformatics 2009; 25: 2078-9.
21. McKenna A, Hanna M, Banks E et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297-303.
22. Koboldt DC, Zhang Q, Larson DE et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012; 22: 568-76.
23. Sherry ST, Ward MH, Kholodov M et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001; 29: 308-11.
24. Consortium T 1000 GP. A map of human genome variation from population-scale sequencing. Nature 2010; 467: 1061-73.
25. Burbano HA, Hodges E, Green RE et al. Targeted investigation of the Neandertal genome by array-based sequence capture. Science 2010; 328: 723-5.
26. Robinson JT, Thorvaldsdóttir H, Winckler W et al. Integrative genomics viewer. Nat Biotechnol 2011; 29: 24-6.
27. Prazeres H, Torres J, Rodrigues F et al. Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells. Oncogene 2011; 30: 1302-17.
28. Lawrence MS, Stojanov P, Polak P et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214-8.
29. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2008; 4: 44-57.
30. Mehra R, Han B, Tomlins SA et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res 2007; 67: 7991-5.
31. Lindberg J, Klevebring D, Liu W et al. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur Urol 2013; 63: 347-53.
32. Cooperberg MR, Simko JP, Cowan JE et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 2013; 31: 1428-34.